Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter.
Acrivon Therapeutics Stock Up 1.9 %
Acrivon Therapeutics stock opened at $5.46 on Thursday. The business has a fifty day moving average of $5.56 and a two-hundred day moving average of $6.73. The firm has a market cap of $170.00 million, a P/E ratio of -2.02 and a beta of 0.85. Acrivon Therapeutics has a twelve month low of $4.69 and a twelve month high of $11.90.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on ACRV shares. Cantor Fitzgerald started coverage on Acrivon Therapeutics in a report on Friday, January 31st. They set an "overweight" rating for the company. KeyCorp started coverage on Acrivon Therapeutics in a report on Friday, January 31st. They set an "overweight" rating for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $23.67.
Read Our Latest Report on Acrivon Therapeutics
About Acrivon Therapeutics
(
Get Free Report)
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Acrivon Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.
While Acrivon Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
